The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted early access to remdesivir in its medicines scheme for conditions with a high unmet medical need.

Gilead’s remdesivir will now be available to adult and adolescent patients with suspected or confirmed severe Covid-19.

This decision was based on a scientific view of the clinical evidence of remdesivir against Covid-19; “the MHRA considers the benefit risk balance of remdesivir in the treatment of COVID-19 to be positive for adult and adolescent patients with severe COVID-19. This evaluation takes into account the threat and risk posed by the ongoing COVID-19 pandemic to patients and public health”. However, the scientific opinion document notes that “a risk management plan (RMP) has been developed to ensure that remdesivir is used as safely as possible.”

MHRA chief executive Dr June Raine said: “We are committed to ensuring that patients can have fast access to promising new treatments for COVID-19.

“We will continue to work closely with the Department of Health and Social Care and other healthcare partners on protecting public health in the UK by prioritising our essential work on clinical trials, access to medicines, and the development of vaccines.

The UK regulator’s decision to allow unlicensed use of remdesivir follows on from similar moves by the US Food and Drug Administration and the European Medicines Agency earlier this month.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.